Increasing BCMA Surface Expression with Gamma Secretase Inhibitor Nirogacestat May Enable Deep and Durable Responses to ALLO-715, an Investigational Anti-BCMA Allogeneic CAR T Therapy SOUTH SAN FRANCISCO, Calif. and STAMFORD, Conn. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer, today announced that David Chang , M.D.,